Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier
This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody
Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development.
The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections.
Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.'
BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise.
MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025.
The full publication can be accessed here.
-Ends-
Contacts
Memo Therapeutics AG
info@memo-therapeutics.com
ICR Healthcare
Amber Fennell, Ashley Tapp
memotx@icrhealthcare.com
+44 (0)20 3709 5700
About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn.
Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at www.memo-therapeutics.com, and on LinkedIn.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients
PARIS--(BUSINESS WIRE)-- SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABK led by Pr. Samira FAFI-KREMER, Director of the Institut de Virologie de Strasbourg and Pr. Pascal POIGNARD, Head of the "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble. This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients. Since the option agreement signed in 2024, SpikImm has already made progress in its preclinical work, and has successfully completed the development of the cell line for GMP manufacturing. The aim is to carry out the first in human studies by 2026. BK virus (BKV) infects most individuals early in life and typically remains latent without causing disease. However, under immunosuppressive treatment, in particular in transplant patients, BKV can reactivate and replicate in the urinary tract, leading to potentially serious complications. In kidney transplant recipients; BKV reactivation may result in graft loss and increase the risk of bladder cancer. In addition, BKV is responsible for severe hemorrhagic cystitis in bone marrow graft recipients. No BKV-specific antiviral therapies or vaccines are currently available. Therefore, there is an urgent medical need for the development of novel anti-BKV prophylactic treatments. Thanks to the work of Pr. FAFI-KREMER, Head of renowned Institut de Virologie of Strasbourg (U1109 University of Strasbourg / Inserm, Strasbourg University Hospitals) and her team, the key role of anti-BKV neutralizing antibodies for protection against BKV infection and associated diseases was uncovered. Building upon these insights, Pr. FAFI-KREMER and Pr. POIGNARD joined forces to develop anti-BKV neutralizing monoclonal antibodies under the HuMABK project, funded by ANR and SATT Conectus. The expertise in antibody discovery of Pr. POIGNARD and collaborators of the Institut de Biologie Structurale (CEA/CNRS / University of Grenoble Alpes / UMR 5075) enabled the successful isolation of broad and potent anti-BKV neutralizing human monoclonal antibodies. These monoclonal antibodies represent promising candidates for future clinical development as potential best-in-class options. SpikImm and SATT Conectus today announced the signature of a worldwide exclusive licensing agreement for the anti-BKV monoclonal antibodies. These antibodies are engineered to potentially provide effective, long-lasting protection against the serious complications associated with BKV, offering a prophylactic solution for transplant recipients. With its partners Institut Pasteur and LFB, SpikImm has already demonstrated its expertise in rapidly bringing from discovery to clinical trials two anti-SARS COV2 monoclonal antibodies within twelve months, creating a unique platform for the accelerated discovery and development of monoclonal antibodies to the benefit of patients. SpikImm is focused on the accelerated development of long-acting monoclonal antibodies to protect immunocompromised patients from several viral infections, including SARS-CoV-2 and BKV. Pr. FAFI-KREMER, PharmD, PhD, University Professor-Hospital Practitioner, Head of Institut de Virologie de Strasbourg (U1109 University of Strasbourg / Inserm, Strasbourg University Hospitals) and Pr. POIGNARD, M.D., Ph.D, University Professor-Hospital Practitioner (University of Grenoble Alpes - CHU Grenoble-Alpes), Head of "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble (CEA-CNRS-UGA Mixed Research Unit 5075) comment: "Reactivation of the BK virus in patients receiving kidney transplant, bone marrow or stem cell grafts has potential serious consequences and represents a growing medical challenge. The HuMABK monoclonal antibodies discovered by Grenoble's Institut de Biologie Structurale in collaboration with Strasbourg's Institut de Virologie are remarkably effective in neutralizing this virus and represent a promising antiviral strategy. We are convinced that the collaboration with SpikImm will ensure a rapid clinical development. Specifically, we anticipate that the monoclonal antibodies will significantly enhance patient care, notably by preserving kidney transplants, and promoting favorable outcomes in bone marrow recipients. ' James PHILLIPS, MD, CEO of SpikImm, comments: "We are delighted to sign this agreement for these highly promising monoclonal antibodies against the BK virus. SpikImm will be able to draw on the exceptional quality of the research team, as well as the strong support of SATT Conectus, to advance this project and bring new hope to the vulnerable immunocompromised patients.' Philippe POULETTY, MD, chairman of SpikImm comments " SpikImm's mission is to protect immunocompromised patients from severe viral diseases. These potent anti-BKV monoclonal antibodies will reinforce SpikImm's pipeline to offer broad protection against several severe infections. SpikImm embodies Truffle Capital approach: to actively create and grow companies with outstanding science to address major unmet needs.' Emmanuel POTEAUX, Chairman and CEO of SATT Conectus, highlights: " The signing of this technology licence marks an outstanding scientific collaboration between two leading researchers working at the heart of two regions of academic excellence, Alsace and Grenoble. The combined financial investment from the ANR and SATT Conectus made it possible to obtain and validate robust preclinical results, paving the way for clinical development. We are delighted that SpikImm is taking over to continue the development of this major health innovation for patients.' The HuMABK project is supported by: About SpikImm SpikImm is a French clinical-stage biotech founded by Truffle Capital in collaboration with Institut Pasteur in 2021 to develop human monoclonal antibodies for the prevention of severe infectious diseases affecting immunocompromised patients. SpikImm's lead candidates SPK001 and SPK002, have been originally developed in the laboratory of Humoral Immunology (Institut Pasteur & Inserm U1222) headed by Dr Hugo MOUQUET, as long-acting monoclonal antibodies for the prevention of COVID-19 in immunocompromised patients. SpikImm is currently expanding its portfolio of monoclonal antibodies against severe viral infections, through collaborations with prestigious academic research teams, starting with BKV infection. More information: About Truffle Capital Founded in 2001, Truffle Capital is an independent European Venture Capital firm specializing in Life Sciences (MedTech and BioTech) and disruptive technologies in the I.T. sector (FinTech and InsurTech). Truffle Capital's mission is to support the creation and development of young innovative companies capable of becoming tomorrow's leaders. Managed by Dr. Philippe Pouletty and Bernard-Louis Roques, co-founders and CEOs, Truffle Capital has €500 million in assets under management. It has raised more than €1.2 billion since its creation and has supported more than 70 companies in the digital technology and life sciences sectors. More information: — Twitter: @trufflecapital About SATT Conectus SATT* Conectus is the main entry point for business partners and companies to access all the innovations and capabilities from public research in Alsace, one of the top ranked territories for the excellence of research in France. Thanks to its investment fund, SATT CONECTUS offers advanced, applicative technologies whose proofs of concept have been established, and ready to industrialize. Therefore investors will have access to groundbreaking startups built around those breakthrough yet matured technologies. Another type of collaboration allows companies to co-develop high potential innovative projects with public research, in order to tailor them to their specific needs. * technology transfer acceleration organization More information: About the Institut de Virologie de Strasbourg The Institut de Virologie de Strasbourg, headed by Pr. FAFI KREMER is affiliated with the Faculty of Medicine of the University of Strasbourg, the Strasbourg University Hospitals and the Inserm Unit U1109, LabEx TRANSPLANTEX. For more than 10 years, his research has focused on the study of virus-host interaction in the pathogenesis of polyomaviruses (BK virus)-associated diseases in immunocompromised individuals, particularly transplant patients. The central aim is to ultimately identify accurate and personalized biomarkers and to develop urgently needed, preventive and therapeutic antiviral strategies. About the Institut de Biologie Structurale (IBS) The IBS, a mixed research unit CEA-CNRS-Université Grenoble Alpes (UMR 5075), hosts the "Antibodies and Infectious Diseases" research team headed by Pr. POIGNARD, specialized in the study of humoral responses to viral, bacterial and parasitic infections. After playing a key role in the discovery of broadly neutralizing antibodies against HIV, P Poignard has extended his interest to other viruses, such as the BK virus, but also to bacteria and parasites. In particular, his team focuses on the development of innovative strategies for the discovery of human monoclonal antibodies to develop new therapeutic approaches and help vaccine design.
Gizmodo
a day ago
- Gizmodo
Bill Nye the Science Guy to RFK Jr: ‘Okay No More Texts'
Bill Nye, the science educator who's been a TV mainstay for decades, is not the kind of guy you'd expect would be friends with Robert F. Kennedy Jr., the most prominent anti-science kook in the country. But apparently they go way back. And Nye is getting sick of all the texts he's getting from Kennedy spouting absolute garbage. Nye met Kennedy 'many years ago,' according to a new profile of The Science Guy in Men's Health magazine, after the two men were introduced by actor Ed Begley Jr. to talk about environmental issues. Nye told the magazine that Kennedy, who's now the head of the Department of Health and Human Services, sends him endless texts. 'Just no self-awareness,' Nye said of Kennedy. 'And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection.' Kennedy has long been an anti-vaccine extremist, working from 2015-2023 as chair of the Children's Health Defense. The health secretary has previously said 'there's no vaccine that is safe and effective' and has worked to limit access to vaccines, risking the lives of millions of Americans. Nye told Men's Health that he responded to the texts by saying he'd read Kennedy's book, though it's not clear which one. Kennedy has contributed to quite a few anti-science screeds, including books like Vax-Unvax: Let the Science Speak, The Wuhan Cover-Up, and 2021's The Real Anthony Fauci. That last one includes a section where Kennedy promotes 'miasma theory' and rejects germ theory. Miasma theory was abandoned in the 19th century, while the germ theory of disease is foundational to our 21st-century understanding of how diseases spread. Nye told the magazine that after he got 'miles and miles' of texts from Kennedy, he finally said, 'Okay, no more texts,' concluding Kennedy simply wasn't suited for the job he's holding in the Trump administration. Kennedy is a dangerous lunatic who doesn't even believe in germ theory. But he's going to do a lot of damage before he leaves his job. And it's already happening. Kennedy's so-called Make America Healthy Again commission issued a report last month that was riddled with errors and cited studies that don't exist. And earlier this week, Kennedy fired all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP). Those are the folks who help steer the country's vaccine policies. The FDA under Kennedy is also reportedly using AI to help approve new drugs, something that boggles the mind when you remember just how unreliable AI can be. Kennedy has repeatedly touted 'spirituality' as a fix to America's health crisis, something Trump's new pick to be Surgeon General has emphasized as well. Kennedy has long claimed that vaccines cause autism, and promised during a White House event back in April that he would reveal the 'cause' of autism by the fall. Science doesn't work with that kind of certainty or timetable, announcing the cause of a given disease like you're unveiling a new Star Wars show before the holidays. But we're not dealing with serious people, as Trump has taken charge, booting scientific experts in favor of the weirdest people on the planet. The Science Guy may try to be diplomatic when it comes to his old friend, 'Bobby' Kennedy, as he calls him in the new Men's Health article. But when even your friends are saying you don't have 'good judgment' in national magazines, something is way off.
Miami Herald
2 days ago
- Miami Herald
Elon Musk finally gets some good news from Jeff Bezos
The future of space transportation is looking increasingly complicated, as the falling-out between SpaceX CEO Elon Musk and U.S. President Donald Trump drags on. After Musk levied strong accusations against Trump and publicly stated he would not have been elected without his support, the president struck back with threats to cancel several SpaceX contracts. This leaves the company's short-term future in a precarious position, jeopardizing Musk's ambitions of colonizing Mars. Don't miss the move: Subscribe to TheStreet's free daily newsletter Multiple space stocks responded to news of this conflict by surging, as investors looked to capitalize on SpaceX's questionable future. But one of Musk's primary rivals, a fellow privately held space exploration company, also recently revealed some less-than-positive news. Blue Origin, owned by Amazon founder Jeff Bezos, recently made an announcement regarding its plans for the future, which could be regarded as good news for SpaceX and Musk. Image source: Terence Lewis/Icon Sportswire via Getty Images While they both rose to fame founding companies that aren't direct competitors, Musk and Bezos are clear rivals in the space race. SpaceX and Blue Origin are both privately held and focused on space exploration and rocket technology. Related: Tesla faces new challenge as leader announces exit SpaceX is intended to be Musk's vehicle for colonizing Mars, while Bezos seems intent on cornering the space tourism market, which also includes rivals such as Richard Branson's Virgin Galactic. However, the two private companies are considered the leaders in the space exploration field. Blue Origin, though, recently reported what seems to be a setback. The company had been targeting Spring 2025 for the launch of its New Glenn rocket, a 320-foot-tall (98 meters) spacecraft with a reusable first stage, but now it has announced that the new launch will be held no earlier than (NET) August 15, 2025. CEO David Limp posted about to the delayed launch on X, revealing that one of the mission's key objectives would be to land and recover its booster. "This will take a little bit of luck and a lot of excellent execution," he states, adding that the company is on track to produce GS2s, referring to the second stage of the rocket. Following New Glenn's mostly successful January 2025 mission, the company hasn't indicated more progress toward further launches, even after its leaders initially set high expectations for its rocket launches. Now, as Ars Technica speculates, the August launch may be the only one Blue Origin completes this year. More Elon Musk News: Elon Musk company reveals major leap forwardThe 'anti-Tesla' gives American buyers more good newsElon Musk's DOGE made huge mistakes with veterans' programs While Bezos may not be happy about this launch delay, it is excellent news for Musk, whose own company has seen three rockets explode so far this year. Even before the company's third mission spiraled out of control mid-flight, regulators had expressed concern about possible safety risks for people on the ground. There's no denying that both companies have faced challenges this year, as both race to outmaneuver each other and establish themselves as the leader of the space exploration market. Recent projections show that the space economy is expected to reach a $944 billion valuation by 2033, revealing a lot of room to run for companies. Related: Space stocks soar as Elon Musk and Donald Trump argue The problems plaguing both companies, though, raise the question of which one is better positioned to keep growing. SpaceX has launched several rockets this year, but its track record hasn't been encouraging, given the trend of explosions. And while Blue Origin has delayed its launch, that doesn't mean it will go well when it happens. On top of that, SpaceX still faces the possibility that it may lose out on lucrative federal contracts, unless Musk and Trump's feud is resolved soon. The zero-sum nature of financial markets means that for as long as its prospects appear uncertain, rivals will likely continue to gain. In this case, the list of companies that may benefit from SpaceX's uncertain future includes Blue Origin. Related: Billionaire fund manager, skeptical of AI, backs shocking stock The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
